Mesoblast company profile
Company profile
Mesoblast has 108 employees and is headquartered in Melbourne, Australia.
Melbourne-based Mesoblast has existed since 2004 and works on regenerative medicine products in Australia. Its platform relies on mesenchymal lineage cells, and the portfolio includes Ryoncil, aimed at graft versus host disease in children and at inflammatory bowel conditions, Revascor for hypoplastic left heart syndrome, and remestemcel-L, which is in Phase III trials for heart failure and degenerative back pain. The pipeline also includes MPC-300-IV for rheumatoid arthritis and MPC-25-IC for acute myocardial infarction. Partnerships with Tasly Pharmaceutical Group, Grünenthal GmbH and JCR Pharmaceuticals Co. Ltd. cover several of the candidates under development.
In the fiscal year ended June 2026, Mesoblast reported revenue of 120.3 million US dollars and a net loss of 57.5 million US dollars. The company employs 108 people at its headquarters in Melbourne, and the figures are stated in US dollars.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Headquarters
- 55 Collins Street, 3000, Melbourne
- Employees
- 108
- Chief executive
- Silviu Itescu
- Founded
- 2004
- Fiscal year
- July - June
- Listing
- MSB · ASX
- Indices
- S&P/ASX 200
- Currency
- AUD
- ISIN
- AU000000MSB8
- Website
- mesoblast.com
Mesoblast and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| MesoblastMSB | Australia | $1.48B | 108 | -42.6% | — |
| Neuren PharmaceuticalsNEU | Australia | $1.83B | 8 | 19.9% | 144.0 |
| Metis TechBio7666 | Hong Kong SAR China | $1.11B | 150 | -131.2% | — |
| InSilico Medicine Cayman TopCo3696 | Hong Kong SAR China | $2.59B | 333 | -6.9% | — |
| Telix PharmaceuticalsTLX | Australia | $2.92B | 1,120 | 6.2% | 92.3 |
| 3SBio1530 | Hong Kong SAR China | $4.56B | 6,068 | 60.3% | 3.90 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
